Earnings

Boundless Bio Q2 EPS $(1.06) Misses $(0.61) Estimate

Aug 10, 2026 · 05:46 AM ET· updated 1h ago

Boundless Bio (NASDAQ:BOLD) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $(0.61) by 73.77 percent. This is a 51.43 percent decrease over losses of $(0.70) per share from

Why It Matters

Boundless Bio lost more money per share than experts predicted—like spending way more allowance than you planned. When a company loses more than expected, investors watch to see if the company has a plan to turn things around.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

BOLD2.90

+0.06 (+1.94%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.